Reported 15,000,000 shares, unchanged from the prior quarter.
Reported value -16.2%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 20754000 |
| 2021-12-31 | 10910000 |
| 2022-03-31 | 8942000 |
| 2022-06-30 | 8380000 |
| 2022-09-30 | 5974000 |
| 2022-12-31 | 4623611 |
| 2023-03-31 | 7473611 |
| 2023-06-30 | 7848611 |
| 2023-09-30 | 5622500 |
| 2023-12-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q4 2023 | Unchanged | 0 | 0 (0.0%) | 0 | $0 | 2024-02-14 | |
| Q3 2023 | Unchanged | 0 | 0 (0.0%) | 1.03% | $5,622,500 | 2023-11-14 | |
| Q2 2023 | Unchanged | 0 | 0 (0.0%) | 1.06% | $7,848,611 | 2023-08-14 | |
| Q1 2023 | Reduced | 0 | -10,000,000 (-100.0%) | 1.0% | $7,473,611 | 2023-05-15 | |
| Q4 2022 | Unchanged | 10,000,000 | 0 (0.0%) | 0.66% | $4,623,611 | 2023-02-14 | |
| Q3 2022 | Reduced | 10,000,000 | -5,000,000 (-33.3%) | 0.72% | $5,974,000 | 2022-11-14 | |
| Q2 2022 | Unchanged | 15,000,000 | 0 (0.0%) | 0.57% | $8,380,000 | 2022-08-15 | |
| Q1 2022 | Unchanged | 15,000,000 | 0 (0.0%) | 0.41% | $8,942,000 | 2022-05-16 | |
| Q4 2021 | Unchanged | 15,000,000 | 0 (0.0%) | 0.66% | $10,910,000 | 2022-02-14 | |
| Q3 2021 | Unchanged | 15,000,000 | 0 (0.0%) | 1.27% | $20,754,000 | 2021-11-15 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
49 managers reported BRIDGEBIO PHARMA INC for Q3 2021.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | Added | 114,950,000 | +41,500,000 | 0.03% | $158,746,000 | 3 qtrs |
| WOLVERINE ASSET MANAGEMENT LLC | Unchanged | 0 | 0 | 0.99% | $114,303,000 | 3 qtrs |
| DEERFIELD MANAGEMENT COMPANY L P SERIES C | Unchanged | 80,000,000 | 0 | 2.16% | $110,499,000 | 3 qtrs |
| LAZARD ASSET MANAGEMENT LLC | Added | 41,500,000 | +16,500,000 | 0.06% | $57,362,000 | 3 qtrs |
| Bank of America Corporation | Added | 34,995,000 | +157,000 | < 0.01% | $48,196,000 | 3 qtrs |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | Reduced | 21,000,000 | -28,655,000 | 0.77% | $29,010,000 | 3 qtrs |
| STATE STREET CORPORATION | Added | 16,605,000 | +1,800,000 | < 0.01% | $22,954,000 | 3 qtrs |
| Calamos Advisors LLC | Added | 16,000 | +10,000 | 0.1% | $22,119,000 | 3 qtrs |
| TFG Asset Management GP Ltd This report | Unchanged | 15,000,000 | 0 | 1.27% | $20,754,000 | 2 qtrs |
| Aequim Alternative Investments LP | Reduced | 14,800,000 | -19,200,000 | 0.79% | $20,457,000 | 3 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2021
- Filed
- November 15, 2021
- Filing type
- 13F-HR
- Position type
- NOTE 2.500% 3/1
Voting authority reported
- Sole
- 0
- Shared
- 15,000,000
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.